Endo International PLC (NASDAQ:ENDP) was the recipient of a large drop in short interest during the month of September. As of September 30th, there was short interest totalling 12,911,376 shares, a drop of 19.3% from the September 15th total of 16,003,377 shares. Currently, 6.5% of the company’s shares are short sold. Based on an average trading volume of 7,508,091 shares, the short-interest ratio is presently 1.7 days.

Endo International PLC (NASDAQ:ENDP) opened at 19.85 on Wednesday. Endo International PLC has a 12-month low of $12.56 and a 12-month high of $68.84. The stock’s market capitalization is $4.42 billion. The firm has a 50-day moving average of $20.62 and a 200 day moving average of $20.24.

Endo International PLC (NASDAQ:ENDP) last issued its quarterly earnings data on Monday, August 8th. The company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.74 by $0.12. Endo International PLC had a negative net margin of 25.90% and a positive return on equity of 15.54%. The firm had revenue of $921 million for the quarter, compared to analyst estimates of $873.50 million. During the same period in the prior year, the business posted $1.08 EPS. The business’s revenue for the quarter was up 25.3% compared to the same quarter last year. On average, analysts predict that Endo International PLC will post $4.56 earnings per share for the current fiscal year.

A number of research analysts recently commented on ENDP shares. Vetr raised shares of Endo International PLC from a “hold” rating to a “buy” rating and set a $21.95 price target for the company in a report on Thursday, August 25th. Mizuho reaffirmed a “buy” rating and issued a $29.00 price target on shares of Endo International PLC in a report on Monday, September 19th. Northland Securities raised shares of Endo International PLC from a “market perform” rating to an “outperform” rating and set a $27.00 price target for the company in a report on Thursday, September 29th. Morgan Stanley set a $16.00 price target on shares of Endo International PLC and gave the company a “hold” rating in a report on Thursday, September 8th. Finally, Leerink Swann reaffirmed a “market perform” rating and issued a $23.00 price target on shares of Endo International PLC in a report on Wednesday, June 29th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $37.50.

Several institutional investors have recently modified their holdings of the company. RS Investment Management Co. LLC raised its position in shares of Endo International PLC by 0.4% in the second quarter. RS Investment Management Co. LLC now owns 1,374,185 shares of the company’s stock valued at $21,424,000 after buying an additional 6,132 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Endo International PLC by 0.9% in the first quarter. Geode Capital Management LLC now owns 1,759,167 shares of the company’s stock valued at $49,422,000 after buying an additional 15,173 shares in the last quarter. Meeder Asset Management Inc. bought a new position in shares of Endo International PLC during the first quarter valued at approximately $139,000. Babson Capital Management LLC raised its position in shares of Endo International PLC by 225.1% in the first quarter. Babson Capital Management LLC now owns 73,800 shares of the company’s stock valued at $2,077,000 after buying an additional 51,100 shares in the last quarter. Finally, Aperio Group LLC raised its position in shares of Endo International PLC by 1.7% in the first quarter. Aperio Group LLC now owns 43,200 shares of the company’s stock valued at $1,216,000 after buying an additional 732 shares in the last quarter. Hedge funds and other institutional investors own 96.54% of the company’s stock.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

5 Day Chart for NASDAQ:ENDP

Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.